EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Raza, Karim

DOI:
10.1136/annrheumdis-2016-209846

Citation for published version (Harvard):

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 14. Jan. 2019
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

Hanna W. van Steenbergen1, Daniel Aletaha2, Liesbeth J.J. Beaart-van de Voorde1, Elisabeth Brouwer3, Catalin Codreanu4, Bernard Combe5, João E. Fonseca6, Merete L. Hetland7, Frances Humby8, Tore K. Kvien9, Karin Niedermann11, Laura Nuño12, Sue Oliver13, Solbritt Rantapää-Dahlqvist14, Karim Raza15, Dirkjan van Schaardenburg16, Georg Schett17, Liesbeth De Smet1, Gabriella Szücs18, Jiri Vencovský19, Piotr Wiland20, Maarten de Wit21, Robert L. Landewè10, Annette H.M. van der Helm-van Mil1, 22

1. Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands
2. Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
3. Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, the Netherlands
4. Rheumatology Department, Center of Rheumatic Diseases, Bucharest, Romania
5. Department of Rheumatology, Montpellier University Hospital, Montpellier, France
6. Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Portugal
7. DANBIO registry and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
8. Queen Mary University of London, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Charterhouse Square, London, United Kingdom
9. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
10. Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands and Atrium Medical Center, Heerlen, the Netherlands
11. Institute of Physiotherapy, School of Health Professions, Zurich University of Applied Sciences, Winterthur, Switzerland
12. Department of Rheumatology, Hospital Universitario La Paz-IdiPaz, Paseo de La Castellana, Madrid, Spain
13. Independent Nurse Consultant, North Devon, UK
14. Department of Public Health and Clinical Medicine/Rheumatology, University Hospital, Umeå, Sweden
15. Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
16. Amsterdam Rheumatology and immunology Center, locations Reade and Academic Medical Center, Amsterdam, Netherlands
17. Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
18. Department of Rheumatology, University of Debrecen Medical Center, Debrecen, Hungary
19. Department of Rheumatology, First Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic
20. Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland
21. EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
22. Department of Rheumatology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Address for correspondence:
A.H.M. van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, the Netherlands,
Tel.: +31 71 5261290, Fax: +31 71 5266752, email: AvdHelm@lumc.nl

Keywords: arthralgia, rheumatoid arthritis, definition, early, definition
ABSTRACT

*Background* During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience.

*Methods* The taskforce consisted of 18 rheumatologists, 2 patients, 3 health professionals and 1 fellow. The process had three phases. In phase-1, a list of parameters considered characteristic for clinically suspect arthralgia (CSA) was derived; the most important parameters were selected by a three-phased Delphi-approach. In phase-2, the experts evaluated 50 existing patients on paper, classified them as CSA/no-CSA and indicated their level of confidence. A provisional set of parameters was derived. This was studied for validation in phase-3, where all rheumatologists collected patients with and without CSA from their outpatient clinics.

*Results* The comprehensive list consisted of 55 parameters, of which 16 were considered most important. A multivariable model based on the data from phase-2 identified 7 relevant parameters: symptom duration <1-year, symptoms of MCP-joints, morning stiffness duration ≥60 minutes, most severe symptoms in early morning, first-degree relative with RA, difficulty with making a fist, positive squeeze-test MCP-joints. In phase-3, the combination of these parameters was accurate in identifying arthralgia patients who were considered at risk of developing RA (AUC=0.92, 95%CI=0.87-0.96). Test characteristics for different cut-off points were determined.

*Conclusion* A set of clinical characteristics for patients with arthralgia who are at risk of progression to RA was established.
INTRODUCTION

The development of rheumatoid arthritis (RA) is a multistep process. A European League Against Rheumatism (EULAR) study group differentiated the following phases: (1) presence of genetic and environmental risk factors for RA, (2) systemic autoimmunity associated with RA, (3) symptoms without clinical arthritis, (4) unclassified arthritis and finally (5) RA.[1] The symptomatic phase preceding clinical arthritis is the first opportunity to clinically recognise patients who are at risk for progression to RA. In contrast to the other phases that have been studied extensively, this phase is less well studied. Whilst a few studies reported on symptoms experienced by patients in this phase and on their impact on daily life,[2–4] clinical characteristics that are specific for this phase have not yet been identified by a consensus-based approach.[1,5,6] This situation hampers the conduct of studies and clinical trials in this phase of the disease. It has been shown that early initiation of disease modifying anti-rheumatic drug (DMARD) treatment in RA is more effective in modulating the erosive and persisting nature of RA compared to delayed initiation of DMARD treatment.[7–9] Hence interventions in the initial clinical phase of the disease, which precedes the onset of clinical arthritis, may be more effective in reducing the risk of disease persistence and the development of damage.[10] However, studies to address this require the inclusion of homogeneous sets of patients.

Clinical expertise, which includes pattern recognition, guides decisions in daily practice and has also been used as reference for the development of several tools or criteria in the field of rheumatology.[11–14] Patients with Clinically Suspect Arthralgia (CSA) have articular symptoms without signs of arthritis and are considered to be at increased risk for progression to RA.[15] Hence, the identification of the presence of CSA is based on clinical
expertise. Recent data revealed that patients with CSA constitute only a small percentage of all patients with arthralgia who visit the rheumatology outpatient clinic for the first time (~7%), and that a proportion of patients with CSA did indeed progress to RA during follow-up (~20%).[16] It was also suggested that clinical experience was accurate to distinguish patients with arthralgia at risk of RA from other arthralgia patients (OR 55). In particular, only a minority of patients who presented with arthralgia and subsequently developed RA were not recognised by the rheumatologist.[17]

Although the concept of CSA is appropriate for use in clinical practice, a drawback is its subjectivity, which may result from differences in practice and experience. Therefore the phenotype of CSA needs to be defined. This taskforce aimed to identify a combination of clinical features that best characterise patients with arthralgia who are at risk of RA according to an expert multidisciplinary group of European rheumatologists, other health professionals and patients. This approach was similar to that which led to the definition of inflammatory back pain, a definition which was subsequently integrated in the ASAS classification criteria.[18,19] The taskforce intended to derive a set of clinical parameters to enable the inclusion of homogeneous sets of patients in subsequent studies. It was considered inappropriate to use the phrase ‘classification criteria’ for the product as, basically, classification concerns testing the presence or absence of a disease. CSA is not in itself a disease, but a combination of symptoms and signs. It was anticipated that clinical characteristics alone are insufficient predictive for RA, that a combination of clinical and other factors (e.g. autoantibodies, imaging results) are necessary to identify patients with imminent RA, and that the derived clinical definition can later become part of criteria for imminent RA. Thus in sum, the present taskforce aimed to define arthralgia at risk for RA.
METHODS

Expert committee
The expert committee comprised 18 rheumatologists, one methodologist (RL, who was also one of the rheumatologists), two nurse specialists, one physiotherapist, two patients and one research fellow, originating from 15 European countries. The target populations are rheumatologists and health professionals working in secondary care.

Three-phased process
The process consisted of three phases and two meetings. Expert opinion was the reference. Per phase consensus was obtained before proceeding to the next phase.

Phase-1
Phase-1 aimed to develop a comprehensive list of clinical parameters (both symptoms at history taking and signs at physical examination) that were considered by the experts to be relevant to distinguish arthralgia that precedes RA from other types of arthralgia. A modified Delphi approach was used. First, all taskforce members were asked to indicate all symptoms and signs that they considered potentially relevant. All parameters mentioned to be relevant by at least two experts or by the patients (based on personal experience) were added to create a comprehensive list. In the next three quantitative rounds the participants selected the parameters they considered most relevant by weighing. After each round, the list of parameters was modified based on the results; parameters on which consensus was reached (either relevant or irrelevant) were not evaluated in the next round. The group response of the previous round and the modified list were presented to the group before they voted in the next round.
**Phase-2**

Phase-2 aimed to develop a provisional set of clinical parameters describing CSA. The experts reviewed clinical data from 50 patients who had previously presented with arthralgia but without clinically detectable arthritis to the rheumatology outpatient clinic of the Leiden University Medical Centre (the Netherlands). Of these, 26 were considered to have CSA by the treating rheumatologist[15]; the prevalence of CSA in this patient set was thus artificial and much higher than in a general rheumatology outpatient clinic. The experts were blinded for grouping by the treating rheumatologists. Clinical data relating to the parameters selected in Phase-1 were presented to the experts as being present or absent in these ‘paper patients’. The experts were asked to classify each patient as having CSA or no-CSA and to provide the level of confidence with their classification on a numerical rating scale from 0 (not confident) to 10 (very confident).

Two approaches were used to analyse the data from Phase-2. First, to gain insight into the degree of equivalence of the expert classifications, the frequencies of the classifications were plotted against the level of confidence of each classification per patient, as described previously.[19] Individual histograms represented all experts’ judgments on individual patient and were evaluated independently by three reviewers (AvdHvM, RL, HvS); each reviewer decided whether the experts agreed on the classification as ‘CSA’, ‘no-CSA’ or ‘unclassifiable’. If all reviewers had the same judgment the patient was categorised accordingly. Otherwise, agreement between the reviewers was reached on how to categorise a patient. The parameters selected in phase-1 were compared for the patients in the three groups (CSA, no-CSA and unclassifiable). Then, to statistically identify the parameters that best discriminated between CSA and no-CSA, a multilevel model was used with one level being
the expert and the other level being the patient; this analysis which was done on 900 judgments about CSA included the data of all 50 patients, each classified by 18 rheumatologists. This mixed effects model with crossed random effects was applied with the weighted CSA classification as outcome and the clinical parameters as independent variables. This model was used to take into account that each expert assessed the same 50 patients. Crossed random effects were included as the symptoms are nested in the combination of expert and patient and thus the residuals of the two levels are still correlated, even after taking the two levels of the analysis into account.[20,21] Clinical parameters with a p-value ≤0.05 in univariable analyses were included in multivariable analysis. The parameters with a positive coefficient in the multivariable analysis were combined to a provisional set of parameters describing CSA. These data were presented at the first meeting.

**Phase-3**

Phase-3 aimed to validate the provisional set of parameters in the outpatient clinics of the participating rheumatologists. They were asked to select newly referred patients without a defined time limit of symptoms and without arthritis but with arthralgia who they considered to have an increased risk of RA based on history taking and physical examination (patients with CSA) and patients who had no evident diagnosis or explanation for the arthralgia at first visit but were not considered at risk for RA (no-CSA). Patients who at presentation had evident diagnoses, such as fibromyalgia or osteoarthritis, were not included in the no-CSA group. In addition, the participants were encouraged to base the decision of CSA on the clinical presentation only and not on results of additional investigations. Due to differences in health care settings, some rheumatologists had access to the result(s) of laboratory or imaging investigation(s) at first presentation for the majority of their patients. The presence or absence of additional test results at the time of identification of CSA or no-CSA was recorded. The
provisional set of parameters derived from phase-2 was tested using multivariable logistic regression analyses in the identified CSA and no-CSA patients. Thus again clinical expertise was the reference. The performance of the combination of parameters was assessed using the area under the receiver operating characteristic curve (AUC). Sensitivity and specificity were determined for different cut-off points. The data from this phase were discussed during the second meeting. The final set of parameters was established by voting.

RESULTS

Phase-1 – Identifying relevant parameters for CSA
First, all experts identified as many parameters as possible that they considered relevant when evaluating whether arthralgia patients did or did not have CSA. The total list consisted of 55 parameters (Supplementary Table S1) and included both parameters that were considered to increase and decrease the likelihood of CSA. By selecting and weighing in three rounds, the number of parameters on the list was reduced to 16 (Table 1). Consensus was reached to proceed with these 16 parameters to phase-2.

Phase-2 – Development of provisional set of parameters describing CSA
First, in order to get an overview of the data, each of the 50 patients were classified as having CSA, no-CSA or being unclassifiable based on their individual histograms which represented the classifications of all experts. Seventeen patients were unequivocally classified as no-CSA, 14 as CSA and 19 patients were considered unclassifiable (examples of the histograms are presented in Supplementary Figure S1). Table 1 presents the frequencies of the clinical parameters for the groups of patients identified as no-CSA, unclassifiable and CSA.
Then, using data from all 50 patients, a multilevel model with weighted CSA classification as outcome was used to select the parameters that best discriminated between CSA and no-CSA. Results of univariable and multivariable analyses are presented in Supplementary Table S2. The following 7 variables were presented during the first meeting as a provisional set of parameters describing CSA: joint symptoms of recent-onset (duration <1 year), symptoms located in MCP-joints, symmetric symptoms or signs (bilateral in same joint region), duration of morning stiffness ≥60 minutes, most severe symptoms present in the early morning, difficulty with making a fist and positive squeeze-test of MCP-joints. At the meeting, it was suggested to remove the item symmetry from the multivariable analysis (because of p>0.05 in univariable analysis) and to force MTP-involvement and a positive family history in the analysis (as these items were judged as very relevant by many experts). The results are presented in Supplementary Table S3. Thereafter, consensus was reached on the following 7 parameters to characterise arthralgia that is clinically suspect for progression to RA: joint symptoms of recent-onset (duration <1 year), symptoms located in MCP-joints, duration of morning stiffness ≥60 minutes, most severe symptoms present in the early morning, presence of a first-degree relative with RA, difficulty with making a fist and positive squeeze-test of MCP-joints (Box 1).

Phase-3 – Validation

In total 322 patients with arthralgia were identified in the different centres (Supplementary Table S4), 142 patients with CSA and 180 arthralgia patients without CSA. Of them, 78 and 61 respectively were identified based on clinical information only (i.e. without data relating to additional investigations); these 139 patients were used in the main analysis. When weighing the parameters based on the B coefficient of the logistic regression analysis after rounding the coefficients to whole points, the combination of 7 parameters performed well to explain the
clinical expertise (AUC 0.93, 95%CI 0.89-0.97). When using all variables unweighted, the combination of 7 parameters performed equally well in identifying arthralgia patients who were considered to be at risk of RA by the experts (AUC 0.92, 95%CI 0.87-0.96) (Supplementary Table S5). The experts agreed that unweighted parameters were more convenient. When analysing all 322 patients, similar AUCs were obtained (Supplementary Table S6).

The sensitivities and specificities belonging to the number of positive parameters are presented in Table 2. A sensitivity >90% was obtained in the presence of ≥3 parameters and a specificity >90% in the presence of ≥4 parameters. All taskforce members unanimously agreed that arthralgia that is suspected for progression to RA is defined by the seven parameters presented in Box 1 and that these parameters are to be used in patients with arthralgia but not clinical arthritis in whom there is not a better explanation for the arthralgia.

**DISCUSSION**

The development of RA is a multi-step process. In this project we defined the combination of symptoms and signs that characterise patients at risk of developing RA. In clinical practice, rheumatologists identify patients with CSA based on their expertise. The presence of CSA may trigger rheumatologists to monitor patients closely and/or to undertake specific laboratory testing or imaging. For daily rheumatologic practice the concept of CSA has been shown to be adequate to differentiate patients with arthralgia, [16,17] but it is subjective and this results in heterogeneity. For scientific studies homogeneous sets of patients are required. Therefore, we aimed to capture clinical expertise and represent it in a set of defined clinical parameters. The process incorporated three phases and two meetings, and the product was obtained by a data-driven and consensus-driven approach. Unanimous agreement was
obtained on seven parameters reflecting the aggregated expertise of rheumatologists, health care professionals and patients from fifteen European countries.

This taskforce was able to successfully identify and collate a homogenous and measurable set of clinical parameters of CSA based on clinical expertise of rheumatologic experts for use in future studies. Further longitudinal studies are required to assess if this definition reduces the number of arthralgia patients that need additional testing, and to determine the predictive accuracy of these clinical parameters for the development of RA, both when used alone and in combination with the results of additional investigations. Thus, the result of this taskforce should serve as the basis for the next step, which is the initiation of longitudinal data-driven projects, which ultimately results in the development of criteria for imminent RA. Most likely such criteria will include both clinical and investigation based parameters (such as laboratory and imaging results).

Because a clinical definition alone is unlikely to be sufficiently accurate to identify RA patients in a symptomatic pre-arthritis phase, and because CSA is not a disease but the description of a phenotype, it was decided that the product of this taskforce should not be referred to as ‘classification criteria’ but as a ‘definition’. Furthermore, while the physicians in the taskforce argued that the word ‘patient’ may have an unwarranted connotation, the patient representatives in the task force justified the use of the term ‘patient’ by pointing to the fact that these individuals had presented with pain and other symptoms and had been referred to secondary care.

The parameters characterising arthralgia at risk of RA may serve as the basis for observational studies and intervention trials performed in the symptomatic pre-arthritis phase.
Depending on the study a more sensitive or more specific definition may be preferred. A high sensitivity may be preferred if the clinical criteria are used as first inclusion criterion, as in this situation the number of CSA patients that are missed by the criteria should be low. Subsequently, additional tests can be applied to ensure sufficient specificity. If in contrast, patients are mainly selected based on clinical characteristics, a higher specificity may be preferred to prevent false-positives. Given this, the taskforce deliberately avoided a single cut-off point to define arthralgia at risk of RA, but provided the test characteristics of a spectrum of cut-off points. A high sensitivity (>90%) is obtained if ≥3 out of the 7 parameters are present; a high specificity (>90%) requires the presence of ≥4 of the 7 parameters.

The clinical variables were considered to distinguish arthralgia patients who are at risk of RA from patients with other types of (not specified) arthralgia. Patients that at first presentation clearly had other diagnoses, such as fibromyalgia or osteoarthritis, were not included in the control groups of phases 2 and 3. This is in line with clinical practice, as there is no diagnostic dilemma in the patients with evident diagnoses. Similar to the 2010 ACR/EULAR classification criteria for RA that should not be applied to arthritis patients with diagnoses other than RA [14], the present set of parameters is reserved for patients with arthralgia with no definitive diagnosis but a clinical suspicion of RA.

The definition was derived for use in secondary care. Because of this target population, the taskforce was composed largely of rheumatologists and their expertise was used as a reference. General practitioners were not involved. The taskforce discussed whether our present product may be useful as a referral tool for general practitioners, as has been done by others [22]. Whilst the taskforce was of the opinion that the present set of parameters might also be valuable to identify patients with arthralgia at risk of RA in primary care, it was
agreed that the applicability of the present definition in the primary care setting would need to be assessed through future research in primary care.

It was acknowledged that there may be some redundancy in the seven parameters expressing risk for RA. Further prospective studies will be required to elucidate if one of the parameters can be omitted without losing discriminative ability.

A limitation of our approach is that the experts who developed the list of relevant parameters in Phase-1 and scored the patients in Phase-2 also identified patients for the validation phase. It is possible that the discussions that were held and the data from the first two phases influenced their clinical expertise while selecting patients with CSA and arthralgia patients without CSA. However many experts also involved other colleagues to select patients with CSA from their clinics and these colleagues were not involved in the first two phases of the project.

Differences in health care settings affect the ability to identify patients in a symptomatic phase prior to presenting with clinically apparent arthritis. E.g., between centres and countries there are differences in the possibilities for early access. Some of the differences between health care settings were incorporated by inviting experts from different centres and different countries and by using a consensus-based approach. There were also differences in the extent to which additional investigations were performed prior to the first clinical evaluation in speciality care. As the aim of the taskforce was to provide a clinical definition, and as knowledge of the results of additional investigations may influence the selection of patients in phase 3, patients in whom knowledge of additional investigations were known at first presentation were initially excluded from analyses. This ensured that patients were
exclusively identified on the clinical presentation. However, a sub-analysis including also the other patients did not give different results, revealing robustness of the data.

The taskforce had discussed if the individual parameters needed to be defined. Consensus was derived that this project was not aiming at what definition of a specific domain was best, but rather what domains contribute most to the ‘phenotype’ of CSA, given all the restrictions.

In conclusion, a set of clinical characteristics describing arthralgia at risk of RA was established. The combination of these parameters accurately reflected expert opinion about CSA. Test characteristics were determined for different cut-off points. For a sensitive definition, arthralgia at risk of RA can be defined by the presence of $\geq 3$ parameters and the presence of $\geq 4$ parameters yielded a high specificity. Longitudinal studies are required to determine the predictive accuracy of these clinical parameters alone and when combined with the results of additional investigations, such as laboratory testing or imaging.

ACKNOWLEDGMENT

The authors acknowledge Sofia Ramiro for her help with the statistical analysis.

COMPETING INTERESTS

The authors have no competing interests.

FUNDING

This taskforce developing the presented definition was financially supported by ESCCA.
REFERENCE LIST


Table 1. Parameters that were selected in phase-1, and frequencies of these parameters in the patients that in phase-2 were categorised as CSA, no-CSA or were considered unclassifiable

<table>
<thead>
<tr>
<th></th>
<th>No-CSA (n=17)</th>
<th>Unclassifiable (n=19)</th>
<th>CSA (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History taking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint symptoms of recent-onset (duration &lt;1 year)</td>
<td>41%</td>
<td>74%</td>
<td>92%</td>
</tr>
<tr>
<td>4-10 joints with symptoms</td>
<td>47%</td>
<td>57%</td>
<td>21%</td>
</tr>
<tr>
<td>Symptoms in MCP-joints</td>
<td>35%</td>
<td>63%</td>
<td>93%</td>
</tr>
<tr>
<td>Symptoms in MTP-joints</td>
<td>35%</td>
<td>53%</td>
<td>57%</td>
</tr>
<tr>
<td>Symptoms in several small joint regions (MCP, wrists, PIP, MTP-joints)</td>
<td>35%</td>
<td>68%</td>
<td>93%</td>
</tr>
<tr>
<td>Symmetric symptoms or signs (bilateral in same joint region)</td>
<td>77%</td>
<td>58%</td>
<td>100%</td>
</tr>
<tr>
<td>Duration of morning stiffness ≥60 minutes</td>
<td>6%</td>
<td>37%</td>
<td>71%</td>
</tr>
<tr>
<td>Most severe symptoms in the early morning</td>
<td>27%</td>
<td>69%</td>
<td>90%</td>
</tr>
<tr>
<td>Improvement of symptoms during the day</td>
<td>15%</td>
<td>36%</td>
<td>90%</td>
</tr>
<tr>
<td>Increasing number of joints with symptoms over time</td>
<td>70%</td>
<td>71%</td>
<td>90%</td>
</tr>
<tr>
<td>Patient-experience of swelling of small hand joints</td>
<td>31%</td>
<td>47%</td>
<td>77%</td>
</tr>
<tr>
<td>Presence of a first-degree relative with RA</td>
<td>7%</td>
<td>33%</td>
<td>36%</td>
</tr>
<tr>
<td><strong>Physical examination</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difficulty with making a fist</td>
<td>8%</td>
<td>31%</td>
<td>43%</td>
</tr>
<tr>
<td>Symptom</td>
<td>Percentage 1</td>
<td>Percentage 2</td>
<td>Percentage 3</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Local tenderness involved joints at physical examination</td>
<td>63%</td>
<td>84%</td>
<td>86%</td>
</tr>
<tr>
<td>Positive squeeze-test of MCP-joints</td>
<td>14%</td>
<td>26%</td>
<td>69%</td>
</tr>
<tr>
<td>Positive squeeze-test of MTP-joints</td>
<td>22%</td>
<td>21%</td>
<td>39%</td>
</tr>
</tbody>
</table>

Data on symptoms of recent-onset was missing in 1 patient, on most severe symptoms in early morning in 6 patients, on improvement of symptoms during the day in 8 patients, on increasing number of joints with symptoms over time in 11 patients, on patient-experience of swelling in 2 patients, on difficulty with making a fist, presence of a first-degree relative with RA, local tenderness of joints, squeeze-test of MCP- and MTP-joints in 4 patients.
Table 2. Sensitivities and specificities for the presence of arthralgia at risk of RA with the clinical expertise on CSA as reference

<table>
<thead>
<tr>
<th>Number of parameters present</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1</td>
<td>100.0%</td>
<td>14.1%</td>
</tr>
<tr>
<td>≥ 2</td>
<td>98.4%</td>
<td>53.8%</td>
</tr>
<tr>
<td>≥ 3</td>
<td>90.2%</td>
<td>74.4%</td>
</tr>
<tr>
<td>≥ 4</td>
<td>70.5%</td>
<td>93.6%</td>
</tr>
<tr>
<td>≥ 5</td>
<td>32.8%</td>
<td>100.0%</td>
</tr>
<tr>
<td>≥ 6</td>
<td>16.4%</td>
<td>100.0%</td>
</tr>
<tr>
<td>≥ 7</td>
<td>1.6%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>
Box 1. EULAR defined characteristics describing arthralgia at risk for RA

These parameters are to be used in patients with arthralgia without clinical arthritis and without other diagnosis or other explanation for the arthralgia.

History taking:

- Joint symptoms of recent-onset (duration <1 year)
- Symptoms located in MCP-joints
- Duration of morning stiffness ≥60 minutes
- Most severe symptoms present in the early morning
- Presence of a first-degree relative with RA

Physical examination:

- Difficulty with making a fist
- Positive squeeze-test of MCP-joints